GenFleet Therapeutics Shares Worth HK$1.96 Billion Moved to Standard Chartered Custody

A significant block of GenFleet Therapeutics-B (02595.HK) shares, valued at HK$1.955 billion (approximately US$250 million), was deposited into a custody account at Standard Chartered Bank (Hong Kong), according to the latest filings from the Hong Kong Stock Exchange.

Details of the Transaction

The filing, dated September 3, shows that an unidentified shareholder or group of shareholders transferred 43,730,900 shares into the bank's custody. This transfer represents a substantial 19.65% of GenFleet's total issued share capital.

As a result of the deposit, the total number of GenFleet shares held in custody by Standard Chartered (Hong Kong) increased by 12.44 percentage points. Such large-scale movements into a single custodian are often monitored by investors as they can sometimes precede major transactions, such as a share pledge for financing or preparation for a block trade, though the reason for this specific transfer was not disclosed.

Ad

Operational Context

This shareholding movement comes as GenFleet advances its clinical pipeline. The biopharmaceutical company recently announced that its drug candidate, GFH375, has entered a Phase II study for the first-line treatment of advanced non-small cell lung cancer (NSCLC) with KRAS G12D mutations.

The study is evaluating three different treatment regimens: GFH375 as a monotherapy, in combination with an EGFR monoclonal antibody (cetuximab), or combined with chemotherapy (pemetrexed).